75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 ...
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, ...
NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...
Nektar Therapeutics (NASDAQ:NKTR) released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.
The MarketWatch News Department was not involved in the creation of this content. -- Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across ...
And how many of them are needed to build a house of cards? Just one — if you're willing to decorate it with decimals and call it science. A global analysis claims plastics are responsible for 13.497% ...
Summit Therapeutics Inc.'s HARMONi study met its PFS endpoint but failed to show statistically significant overall survival, casting doubt on U.S. FDA approval prospects. The FDA has signaled it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback